Imaging Study of a CAIX Binder in Metastatic Clear Cell RCC.
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorRayzeBio, Inc.
About this trial
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of a novel Carbonic Anhydrase IX (CAIX) Binder in Subjects with Metastatic Clear Cell Renal Cell Cancer (RCC).
Eligibility criteria
Qualifiers
At least 18 years old at the time of signing the informed consent form (ICF).
Biopsy proven metastatic clear cell renal cell carcinoma (RCC)
Disqualifiers
Subjects taking below mentioned medications that cannot be stopped 5 half-lives prior to RYZ512 administration and cannot be restarted until all study-related imaging is completed: Anticonvulsants, Antipsychotics, Carbonic Anhydrase inhibitors, COX-2 Inhibitors, Sulfatase Inhibitors, Sulfonamides
Women of Childbearing Potential that are pregnant or breastfeeding.
Trial design
Treatments tested in this trial
- RYZ512
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov